Lymphoma Research Foundation awards $4M in grants to 24 scientists

Medical College of Wisconsin Cancer Center receives $27M gift to advance cancer research

The Medical College of Wisconsin announced a $27 million gift from Tim and Barbara Michels and the Michels Family Foundation to the MCW Cancer Center. This represents the largest personal gift ever to the MCW Cancer Center.

June 26, 2026

Vol.52 No.25

In Brief

Fred Hutch announces eight winners of Dr. Eddie Méndez Award

Fred Hutch Cancer Center announced eight recipients of this year’s Dr. Eddie Méndez Scholar Award. The annual award recognizes the work of exceptional early-career scientists who are studying cancer, infectious diseases and basic sciences.

June 26, 2026

Vol.52 No.25

In Brief

UCLA researchers awarded $3.2M NIH grant to improve detection and treatment of glioblastoma

Researchers from the UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million grant from NIH to develop advanced imaging and surgical strategies aimed at improving outcomes for patients with glioblastoma, a fast-growing and aggressive brain tumor.

June 18, 2026

Vol.52 No.24

In Brief

Kara Marshall receives the 2026 McKnight Scholar Award

Kara Marshall, assistant professor of neuroscience and a McNair Scholar at Baylor College of Medicine, received the 2026 McKnight Scholar Award from the McKnight Endowment Fund for Neuroscience.

June 18, 2026

Vol.52 No.24

Clinical Roundup

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase inhibitor, plus a two-year venetoclax and rituximab regimen versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001), according to the results of the phase III BRUIN CLL-322 trial. The study met its primary endpoint of independent review committee-assessed progression-free survival.

June 18, 2026

Vol.52 No.24

Clinical Roundup

Vispa-cel well-tolerated in second-line large B cell lymphoma, ANTLER phase I study finds

Vispa-cel, an off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase I clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma, with the potential to bring the benefit of cell therapy to patients who lack curative options.

June 18, 2026

Vol.52 No.24

Lymphoma Research Foundation awards $4M in grants to 24 scientists

YOU MAY BE INTERESTED IN

Medical College of Wisconsin Cancer Center receives $27M gift to advance cancer research

Fred Hutch announces eight winners of Dr. Eddie Méndez Award

UCLA researchers awarded $3.2M NIH grant to improve detection and treatment of glioblastoma

Kara Marshall receives the 2026 McKnight Scholar Award

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Vispa-cel well-tolerated in second-line large B cell lymphoma, ANTLER phase I study finds

Renew today!

Subscriber content

Never miss an issue!

Login